MENU

Tag: Watchman LAAC Device

Embolism Concerns Prompt Boston Scientific To Suspend Watchman FLX Sales In Europe

Boston Scientific halted the sales of its second-generation Watchman FLX in Europe because of higher-than-expected embolism rates. The complication resulted in one death that was linked to postoperative infection after the device was percutaneously removed.

Life April 6, 2016

FDA Approves Boston Scientific Watchman Afib Heart Device

Boston Scientific's Watchman Left Atrial Appendage Closure (LAAC) Device intends to prevent stroke. It is a non-drug substitute for Warfarin.

Life March 16, 2015

Real Time Analytics